文献速递糖尿病肥胖与代谢综合征

司美格鲁肽对使用自动胰岛素输注系统的1型糖尿病肥胖成人胰岛素减量影响:ADJUST-T1D事后分析

Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.
PubMed 文献 · Diabetes Care · 2026-01-01

ADJUST-T1D事后分析评估司美格鲁肽1 mg/周对1型糖尿病肥胖成人胰岛素剂量与体重关系的影响。26周时总日胰岛素剂量降低22.6%(95%CI -28.3至-17.0),以餐时胰岛素降幅(-30.5%)为主;第4周83%的减量归因于药物直接效应,第26周直接效应与体重减轻各占约一半。

要点

  • 司美格鲁肽1 mg/周使1型糖尿病肥胖成人26周总日胰岛素剂量降低22.6%。
  • 餐时胰岛素降幅(-30.5%)大于基础胰岛素(-15.6%)。
  • 早期减量主要来自药物直接效应,后期体重减轻贡献增加。

核心结论

  • 司美格鲁肽产生快速、持续且以餐时胰岛素为主的减量效应,早期效应大多不依赖体重减轻。

研究设计与样本

  • ADJUST-T1D试验的事后分析,该试验为双盲、多中心、随机、安慰剂对照试验,评估司美格鲁肽1 mg/周用于1型糖尿病合并肥胖成人。
  • 分析比较司美格鲁肽组与安慰剂组26周内总日胰岛素剂量、基础与餐时胰岛素剂量、碳水化合物摄入及用户发起的餐时bolus次数的变化,采用线性混合模型。
  • 采用中介分析区分司美格鲁肽直接效应与体重减轻对胰岛素减量的贡献。

主要发现

  • 从基线至第26周,总日胰岛素剂量显著降低22.6%(95%CI -28.3至-17.0)。
  • 餐时胰岛素降低30.5%(95%CI -39.5至-21.5),基础胰岛素降低15.6%(95%CI -21.5至-9.7)。
  • 司美格鲁肽组基础/总日胰岛素比值从0.56升至0.62(P < 0.001),胰岛素剂量(单位/kg/天)从0.72降至0.60(P < 0.001)。
  • 第4周总日胰岛素剂量降低83%(-11.1单位/天)归因于药物直接效应,17%(-2.3单位/天)归因于体重减轻;第26周直接效应(-11.4单位/天;52%)与体重减轻(-10.5单位/天;48%)各占一半。
  • 每日碳水化合物摄入从基线137 g(95%CI 107-167)降至第26周107 g(95%CI 76-137)。

临床怎么用

  • 对于使用自动胰岛素输注系统的1型糖尿病合并肥胖成人,司美格鲁肽可作为辅助治疗以实现胰岛素减量。
  • 胰岛素减量以餐时胰岛素为主,需相应调整餐时胰岛素剂量并监测血糖。

局限性

  • 本研究为事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between insulin dose reduction and weight loss. RESEARCH DESIGN AND METHODS: Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models. Mediation analysis was used to attribute direct effects of semaglutide versus weight loss on insulin dose reduction. RESULTS: From baseline to week 26, there was a significant 22.6% reduction in TDD (95% CI -28.3 to -17.0), which was driven by greater reductions in bolus insulin (-30.5%; 95% CI -39.5 to -21.5) than basal insulin (-15.6%; 95% CI -21.5 to -9.7). The basal-to-TDD ratio increased from 0.56 to 0.62 (P < 0.001) and insulin dose (in units/kg/day) decreased from 0.72 to 0.60 (P < 0.001) in the semaglutide group. At week 4, an 83% (-11.1 units/day) reduction in TDD was due to a direct drug effect, and 17% (-2.3 units/day) was attributed to weight loss, whereas at week 26, the difference was split evenly between direct effect (-11.4 units/day; 52%) and weight loss (-10.5 units/day; 48%). Daily carbohydrate intake decreased from 137 g (95% CI 107-167) at baseline to 107 g (95% CI 76-137) at 26 weeks. CONCLUSIONS: Semaglutide produced rapid, sustained, and primarily bolus-driven insulin dose reductions, with early effects being largely independent of weight loss in adults with T1D and obesity.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Karakus KE, Akturk HK, Kruger D, et al. Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care. 2026. PMID: 41429002. doi:10.2337/dc25-2249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。